Version 1
: Received: 28 April 2021 / Approved: 29 April 2021 / Online: 29 April 2021 (15:38:30 CEST)
How to cite:
Gurruchaga Sotés, I.; Santander Lobera, C. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). Preprints2021, 2021040780. https://doi.org/10.20944/preprints202104.0780.v1
Gurruchaga Sotés, I.; Santander Lobera, C. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). Preprints 2021, 2021040780. https://doi.org/10.20944/preprints202104.0780.v1
Gurruchaga Sotés, I.; Santander Lobera, C. Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). Preprints2021, 2021040780. https://doi.org/10.20944/preprints202104.0780.v1
APA Style
Gurruchaga Sotés, I., & Santander Lobera, C. (2021). Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC). Preprints. https://doi.org/10.20944/preprints202104.0780.v1
Chicago/Turabian Style
Gurruchaga Sotés, I. and Carmen Santander Lobera. 2021 "Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)" Preprints. https://doi.org/10.20944/preprints202104.0780.v1
Abstract
In clinical guidelines, such as National Comprehensive Cancer Network guidelines, it is embodied as first therapeutic option the combination of erlotinib and bevacizumab, based on a small clinical trial which included patients with HLRCC. With this case report we bring out another treatment option, not described before, with extraordinary results based on the combination of a check-point inhibitor and a tyrosine-kinase inhibitor, based on theoretical tumor immunogenic environment.
Keywords
Hereditary Leyomiomatosis and Renal Cell Cancer; Pembrolizumab; Axitinib
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
